ALNYLAM PHARMACEUTICALS, INC. Annual Operating Lease, Payments in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
Summary
Alnylam Pharmaceuticals, Inc. annual/quarterly Operating Lease, Payments history and growth rate from 2019 to 2023.
  • Alnylam Pharmaceuticals, Inc. Operating Lease, Payments for the quarter ending March 31, 2022 was $10.7M, a 17.8% increase year-over-year.
  • Alnylam Pharmaceuticals, Inc. annual Operating Lease, Payments for 2023 was $46.5M, a 7.89% increase from 2022.
  • Alnylam Pharmaceuticals, Inc. annual Operating Lease, Payments for 2022 was $43.1M, a 2.86% increase from 2021.
  • Alnylam Pharmaceuticals, Inc. annual Operating Lease, Payments for 2021 was $41.9M, a 10.3% increase from 2020.
Operating Lease, Payments, Annual (USD)
Operating Lease, Payments, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $46.5M +$3.4M +7.89% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-15
2022 $43.1M +$1.2M +2.86% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-15
2021 $41.9M +$3.9M +10.3% Jan 1, 2021 Dec 31, 2021 10-K 2023-02-23
2020 $38M +$4.3M +12.8% Jan 1, 2020 Dec 31, 2020 10-K 2022-02-10
2019 $33.7M Jan 1, 2019 Dec 31, 2019 10-K 2021-02-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.